Cargando…

Thromboembolic events in polycythemia vera

Thromboembolic events and cardiovascular disease are the most prevalent complications in patients with polycythemia vera (PV) compared with other myeloproliferative disorders and are the major cause of morbidity and mortality in this population. Moreover, a vascular complication such as arterial or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Griesshammer, Martin, Kiladjian, Jean-Jacques, Besses, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469649/ https://www.ncbi.nlm.nih.gov/pubmed/30848334 http://dx.doi.org/10.1007/s00277-019-03625-x

Ejemplares similares

Current and future treatment options for polycythemia vera
por: Griesshammer, Martin, et al.
Publicado: (2015)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi, Kris, et al.
Publicado: (2016)

Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations
por: Sadjadian, Parvis, et al.
Publicado: (2020)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
por: Wille, Kai, et al.
Publicado: (2023)

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
por: Sekhri, Rohit, et al.
Publicado: (2021)

Genetic Background of Polycythemia Vera
por: Regimbeau, Mathilde, et al.
Publicado: (2022)

Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016)

Polycythemia Vera: Thinking Beyond the Hematocrit
por: Waggoner, Matthew
Publicado: (2023)

Is there a gender effect in polycythemia vera?
por: Palandri, Francesca, et al.
Publicado: (2020)

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review
por: Ianotto, Jean-Christophe, et al.
Publicado: (2019)

Differential cytokine network profile in polycythemia vera and secondary polycythemia
por: Cacemiro, Maira da Costa, et al.
Publicado: (2020)

PB2195: CHARACTERISTICS OF PATIENTS WITH POLYCYTHEMIA VERA: RESULTS FROM A US ELECTRONIC HEALTH RECORDS DATABASE.
por: Hoffman, Ronald, et al.
Publicado: (2023)

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
por: Gisslinger, Heinz, et al.
Publicado: (2023)

Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2012)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

Recent advances in prognostication and treatment of polycythemia vera
por: Marcellino, Bridget K, et al.
Publicado: (2021)

When hemolysis masks polycythemia vera
por: Derrieux, Coralie, et al.
Publicado: (2019)

Lemierre’s Syndrome in an Elderly Female Patient with Polycythemia Vera: Does Polycythemia Vera Predispose to Lemierre’s Syndrome?
por: Kundal, Sanchit V., et al.
Publicado: (2021)

Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera
por: Brusson, Mégane, et al.
Publicado: (2018)

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2022)

Real-world treatments and thrombotic events in polycythemia vera patients in the USA
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Polycythemia Vera and Essential Thrombocythemia Patients Exhibit Unique Serum Metabolic Profiles Compared to Healthy Individuals and Secondary Thrombocytosis Patients
por: Gómez-Cebrián, Nuria, et al.
Publicado: (2021)

Volumetric Splenomegaly in Patients With Polycythemia Vera
por: Lee, Myung-Won, et al.
Publicado: (2022)

New Perspectives on Polycythemia Vera: From Diagnosis to Therapy
por: Iurlo, Alessandra, et al.
Publicado: (2020)

Polycythemia Vera (PV): Update on Emerging Treatment Options
por: Benevolo, Giulia, et al.
Publicado: (2021)

Emerging agents and regimens for polycythemia vera and essential thrombocythemia
por: Shallis, Rory M., et al.
Publicado: (2021)

Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera
por: Benevolo, Giulia, et al.
Publicado: (2023)

Polycythemia vera presenting with bilateral papilledema
por: Nithyanandam, Suneetha
Publicado: (2009)

Electrocardiographic Findings in Patients with Polycythemia Vera
por: Kayrak, Mehmet, et al.
Publicado: (2011)

Hypercalcemia in a Patient with Polycythemia Vera
por: Bae, Eun Hui, et al.
Publicado: (2012)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

Chorea disclosing a polycythemia vera
por: Liu, Guidong, et al.
Publicado: (2014)

An oncolytic parasite to treat polycythemia vera
por: Rizvi, Syeda Taliya, et al.
Publicado: (2015)

Bilateral adrenal hemorrhage in polycythemia vera
por: Bhandari, Shruti, et al.
Publicado: (2016)

Therapy of polycythemia vera: is it time to change?
por: Passamonti, Francesco, et al.
Publicado: (2017)

Polycythemia vera treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Takotsubo Cardiomyopathy Associated with Polycythemia Vera
por: Basnet, Sijan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9pcpo7eou14281arjo69uv9dg9